MINI FUTURE LONG - IPSEN | Market Closed - Börse Stuttgart 11:57:57 2024-05-31 EDT | ||
| 2.05 EUR | +6.77% |
|
| Current month | +51.85% | ||
| 1 month | +51.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IPSEN
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 2.05 | +6.77% |
| 24-05-30 | 1.92 | +1.05% |
| 24-05-29 | 1.9 | -8.21% |
| 24-05-28 | 2.07 | +0.98% |
| 24-05-27 | 2.05 | -8.48% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 11:57 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | IPSEN |
| Issuer | Morgan Stanley |
| WKN | MG30BX |
| ISIN | DE000MG30BX4 |
| Date issued | 2024-04-25 |
| Strike | 99.89 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.37 € |
|---|---|
| Lowest since issue | 1.18 € |
Company Profile
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
-
Consensus: Ipsen
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
120.6
EUR
Average target price
126.4
EUR
Spread / Average Target
+4.81%
- Stock Market
- Certificates
- Certificat
